Genomic Analysis Revealed Mutational Traits Associated with Clinical Outcomes in Osteosarcoma

References

• Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722–735. doi:10.1038/nrc383825319867
   PubMed Web of Science ®Google Scholar
• Gaspar N, Occean BV, Pacquement H, et al. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. Eur J Cancer. 2018;88:57–66. doi:10.1016/j.ejca.2017.09.03629190507
   PubMed Web of Science ®Google Scholar
• Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21(10):2011–2018. doi:10.1200/JCO.2003.08.13212743156
   PubMed Web of Science ®Google Scholar
• Negri GL, Grande BM, Delaidelli A, et al. Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma. J Pathol. 2019;249(3):319–331. doi:10.1002/path.531931236944
   PubMed Web of Science ®Google Scholar
• Sayles LC, Breese MR, Koehne AL, et al. Genome-Informed Targeted Therapy for Osteosarcoma. Cancer Discov. 2019;9(1):46–63. doi:10.1158/2159-8290.CD-17-115230266815
   PubMed Web of Science ®Google Scholar
• Wang D, Niu X, Wang Z, et al. Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases. Cancer Res. 2019;79(1):7–20. doi:10.1158/0008-5472.CAN-18-108630389703
   PubMed Web of Science ®Google Scholar
• Morrow JJ, Khanna C. Osteosarcoma Genetics and Epigenetics: emerging Biology and Candidate Therapies. Crit Rev Oncog. 2015;20(3–4):173–197. doi:10.1615/CritRevOncog.201501371326349415
   PubMedGoogle Scholar
• Lorenz S, Baroy T, Sun J, et al. Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations. Oncotarget. 2016;7(5):5273–5288. doi:10.18632/oncotarget.656726672768
   PubMedGoogle Scholar
• Perry JA, Kiezun A, Tonzi P, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014;111(51):E5564–73. doi:10.1073/pnas.141926011125512523
   PubMed Web of Science ®Google Scholar
• Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49(6):1221–1230. doi:10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E6174200
   PubMed Web of Science ®Google Scholar
• Cao J, Chen L, Li H, et al. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies. Oncologist. 2019;24(12):e1294–e302. doi:10.1634/theoncologist.2019-023631409745
   PubMed Web of Science ®Google Scholar
• Popic V, Salari R, Hajirasouliha I, Kashef-Haghighi D, West RB, Batzoglou S. Fast and scalable inference of multi-sample cancer lineages. Genome Biol. 2015;16:91. doi:10.1186/s13059-015-0647-825944252
   PubMed Web of Science ®Google Scholar
• Gusfield D. Efficient Algorithms for Inferring Evolutionary Trees. Networks. 1991;21(1):19–28. doi:10.1002/net.3230210104
   Web of Science ®Google Scholar
• Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet. 2014;15(9):585–598. doi:10.1038/nrg372924981601
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Jones PH, Wedge DC, et al. Clock-like mutational processes in human somatic cells. Nat Genet. 2015;47(12):1402–1407. doi:10.1038/ng.344126551669
   PubMed Web of Science ®Google Scholar
• Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 2016;17:31. doi:10.1186/s13059-016-0893-426899170
   PubMed Web of Science ®Google Scholar
• Czarnecka AM, Synoradzki K, Firlej W, et al. Molecular Biology of Osteosarcoma. Cancers. 2020;12(8):8. doi:10.3390/cancers12082130
   Web of Science ®Google Scholar
• Saraf AJ, Fenger JM, Roberts RD. Osteosarcoma: accelerating Progress Makes for a Hopeful Future. Front Oncol. 2018;8:4. doi:10.3389/fonc.2018.0000429435436
   PubMed Web of Science ®Google Scholar
• Moriarity BS, Otto GM, Rahrmann EP, et al. A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet. 2015;47(6):615–624. doi:10.1038/ng.329325961939
   PubMed Web of Science ®Google Scholar
• Kim MS, Lee SY, Cho WH, et al. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann Surg Oncol. 2008;15(3):906–914. doi:10.1245/s10434-007-9779-818163171
   PubMed Web of Science ®Google Scholar
• Bousquet M, Noirot C, Accadbled F. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations. Ann Oncol. 2016;27(4):738–744. doi:10.1093/annonc/mdw00926787232
   PubMed Web of Science ®Google Scholar
• Tao J, Jiang MM, Jiang L, et al. Notch activation as a driver of osteogenic sarcoma. Cancer Cell. 2014;26(3):390–401. doi:10.1016/j.ccr.2014.07.02325203324
   PubMed Web of Science ®Google Scholar
• Rickel K, Fang F, Tao J. Molecular genetics of osteosarcoma. Bone. 2017;102:69–79. doi:10.1016/j.bone.2016.10.01727760307
   PubMed Web of Science ®Google Scholar
• Kim H, Zheng S, Amini SS, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015;25(3):316–327. doi:10.1101/gr.180612.11425650244
   PubMed Web of Science ®Google Scholar
• Han G, Wang Y, Bi W. C-Myc overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway. Oncol Res. 2012;20(4):149–156. doi:10.3727/096504012X1352222723223723461061
   PubMed Web of Science ®Google Scholar
• Chen D, Zhao Z, Huang Z, et al. Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Res. 2018;6:11. doi:10.1038/s41413-018-0009-829644114
   PubMed Web of Science ®Google Scholar
• Harting MT, Blakely ML. Management of osteosarcoma pulmonary metastases. Semin Pediatr Surg. 2006;15(1):25–29. doi:10.1053/j.sempedsurg.2005.11.00516458843
   PubMedGoogle Scholar
• Feng W, Dean DC, Hornicek FJ, et al. Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma. Ther Adv Med Oncol. 2020;12:1758835920922055. doi:10.1177/175883592092205532426053
   PubMed Web of Science ®Google Scholar
• Alldinger I, Schaefer KL, Goedde D, et al. Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression. J Cancer Res Clin Oncol. 2007;133(10):749–759. doi:10.1007/s00432-007-0220-217530287
   PubMed Web of Science ®Google Scholar
• Friedmann-Morvinski D, Verma IM. Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep. 2014;15(3):244–253. doi:10.1002/embr.20133825424531722
   PubMed Web of Science ®Google Scholar
• Ge Y, Gomez NC, Adam RC, et al. Stem Cell Lineage Infidelity Drives Wound Repair and Cancer. Cell. 2017;169(4):636–50 e14. doi:10.1016/j.cell.2017.03.04228434617
   PubMed Web of Science ®Google Scholar
• Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–629. doi:10.1038/nrclinonc.2017.4428397828
   PubMed Web of Science ®Google Scholar
• Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer. 2008;8(12):929–941. doi:10.1038/nrc245919005493
   PubMed Web of Science ®Google Scholar
• Lorenzen I, Trad A, Grotzinger J. Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain. Biochem Biophys Res Commun. 2011;415(2):330–336. doi:10.1016/j.bbrc.2011.10.05622033402
   PubMed Web of Science ®Google Scholar
• Le Gall SM, Bobe P, Reiss K, et al. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha. Mol Biol Cell. 2009;20(6):1785–1794. doi:10.1091/mbc.e08-11-113519158376
   PubMed Web of Science ®Google Scholar
• Xu M, Zhou H, Zhang C, et al. ADAM17 promotes epithelial-mesenchymal transition via TGF-beta/Smad pathway in gastric carcinoma cells. Int J Oncol. 2016;49(6):2520–2528. doi:10.3892/ijo.2016.374427779657
   PubMed Web of Science ®Google Scholar
• Liu HB, Yang QC, Shen Y, Zhu Y, Zhang XJ, Chen H. Clinicopathological and prognostic significance of the expression of ADAM17 mRNA and protein in esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi. 2013;35(5):361–365. doi:10.3760/cma.j.issn.0253-3766.2013.05.00924054013
   PubMedGoogle Scholar
• Shou ZX, Jin X, Zhao ZS. Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer. Ann Surg. 2012;256(6):1014–1022. doi:10.1097/SLA.0b013e3182592f5622668812
   PubMed Web of Science ®Google Scholar
• Sun J, Jiang J, Lu K, Chen Q, Tao D, Chen Z. Therapeutic potential of ADAM17 modulation in gastric cancer through regulation of the EGFR and TNF-alpha signalling pathways. Mol Cell Biochem. 2017;426(1–2):17–26. doi:10.1007/s11010-016-2877-927878499
   PubMed Web of Science ®Google Scholar
• Massari ME, Murre C. Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol. 2000;20(2):429–440. doi:10.1128/MCB.20.2.429-440.200010611221
   PubMed Web of Science ®Google Scholar
• Tsung AJ, Guda MR, Asuthkar S, et al. Methylation regulates HEY1 expression in glioblastoma. Oncotarget. 2017;8(27):44398–44409. doi:10.18632/oncotarget.1789728574840
   PubMedGoogle Scholar
• Roma J, Masia A, Reventos J. Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro. Clin Cancer Res. 2011;17(3):505–513. doi:10.1158/1078-0432.CCR-10-016621177409
   PubMed Web of Science ®Google Scholar
• Jia D, Wei L, Guo W, et al. Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma. Hepatology. 2011;54(4):1227–1236. doi:10.1002/hep.2449521688285
   PubMed Web of Science ®Google Scholar
• Rettig EM, Bishop JA, Agrawal N, et al. HEY1 is expressed independent of NOTCH1 and is associated with poor prognosis in head and neck squamous cell carcinoma. Oral Oncol. 2018;82:168–175. doi:10.1016/j.oraloncology.2018.05.01729909892
   PubMed Web of Science ®Google Scholar
• Forghanifard MM, Taleb S, Abbaszadegan MR. Notch Signaling Target Genes are Directly Correlated to Esophageal Squamous Cell Carcinoma Tumorigenesis. Pathol Oncol Res. 2015;21(2):463–467. doi:10.1007/s12253-014-9849-825361534
   PubMed Web of Science ®Google Scholar
• Jiang S, Zhou F, Zhang Y, et al. Identification of tumorigenicity-associated genes in osteosarcoma cell lines based on bioinformatic analysis and experimental validation. J Cancer. 2020;11(12):3623–3633. doi:10.7150/jca.3739332284759
   PubMed Web of Science ®Google Scholar
• Tsuru A, Setoguchi T, Matsunoshita Y, et al. Hairy/enhancer-of-split related with YRPW motif protein 1 promotes osteosarcoma metastasis via matrix metallopeptidase 9 expression. Br J Cancer. 2015;112(7):1232–1240. doi:10.1038/bjc.2015.8425742474
   PubMed Web of Science ®Google Scholar